Table 1.
Type-specific HR-HPV viral loads in the different diagnoses of cervical cytology
| HPV type | Cervical cytology | No. of womena | Mean (SD) of log 10-transformed HPV viral load | P-valueb | |||
|---|---|---|---|---|---|---|---|
| 14 HR-HPVs | NILM | 613 | 3.34 (±0.91) | R | |||
| ASC | 215 | 3.80 (±1.08) | <0.001 | R | |||
| LSIL | 187 | 4.28 (±1.02) | <0.001 | 0.002 | R | ||
| ≥HSIL | 260 | 4.76 (±1.06) | <0.001 | <0.001 | 0.001 | R | |
| ≥AGC | 33 | 3.73 (±0.99) | 0.36 | 1.00 | 0.11 | 0.001 | |
| NILM | 121 | 3.72 (±1.05) | R | ||||
| ASC | 51 | 4.15 (±1.09) | 0.24 | R | |||
| 16 | LSIL | 67 | 4.45 (±0.87) | 0.06 | 0.89 | R | |
| ≥HSIL | 143 | 4.95 (±0.97) | <0.001 | <0.001 | 0.40 | R | |
| ≥AGC | 7 | 4.33 (±0.93) | 0.66 | 1.00 | 1.00 | 0.63 | |
| 18 | NILM | 62 | 3.28 (±1.14) | R | |||
| ASC | 37 | 3.65 (±1.12) | 0.77 | R | |||
| LSIL | 16 | 3.98 (±1.49) | 0.45 | 0.94 | R | ||
| ≥HSIL | 43 | 3.58 (±0.86) | 0.88 | 1.00 | 0.89 | R | |
| ≥AGC | 9 | 3.24 (±0.74) | 1.00 | 0.93 | 0.70 | 0.96 | |
| NILM | 30 | 3.36 (±1.23) | R | ||||
| ASC | 13 | 3.68 (±0.92) | 0.91 | R | |||
| 31 | LSIL | 12 | 3.66 (±0.72) | 0.97 | 1.00 | R | |
| ≥HSIL | 26 | 4.95 (±0.76) | <0.001 | 0.04 | 0.04 | R | |
| ≥AGC | 2 | 3.95 (±0.82) | 0.29 | 0.69 | 0.56 | 1.00 | |
| 33 | NILM | 34 | 3.23 (±0.95) | R | |||
| ASC | 16 | 4.40 (±0.88) | 0.03 | R | |||
| LSIL | 25 | 3.62 (±0.74) | 0.77 | 0.24 | R | ||
| ≥HSIL | 24 | 5.10 (±0.70) | <0.001 | 0.40 | <0.001 | R | |
| ≥AGC | 3 | 4.00 (±1.77) | 0.83 | 0.98 | 0.98 | 0.58 | |
| NILM | 15 | 3.92 (±0.58) | R | ||||
| ASC | 7 | 4.22 (±0.80) | 0.93 | R | |||
| 45 | LSIL | 6 | 4.32 (±0.58) | 0.81 | 1.00 | R | |
| ≥HSIL | 7 | 3.38 (±0.87) | 0.71 | 0.56 | 0.24 | R | |
| ≥AGC | 7 | 3.63 (±0.31) | 0.93 | 0.78 | 0.72 | 0.98 | |
| 52 | NILM | 146 | 3.20 (±0.77) | R | |||
| ASC | 74 | 3.69 (±0.99) | 0.18 | R | |||
| LSIL | 40 | 4.13 (±1.14) | 0.001 | 0.49 | R | ||
| ≥HSIL | 41 | 4.62 (±1.38) | <0.001 | 0.002 | 0.38 | R | |
| ≥AGC | 5 | 3.35 (±1.31) | 1.00 | 1.00 | 0.90 | 0.58 | |
| NILM | 40 | 3.34 (±0.68) | R | ||||
| ASC | 24 | 3.94 (±1.48) | 0.04 | R | |||
| 56 | LSIL | 12 | 3.94 (±1.47) | 0.04 | 1.00 | R | |
| ≥HSIL | 15 | 3.32 (±1.77) | 1.00 | 0.03 | 0.03 | R | |
| ≥AGC | N/A | N/A | N/A | N/A | N/A | N/A | |
| 58 | NILM | 96 | 3.16 (±1.07) | R | |||
| ASC | 49 | 3.99 (±1.03) | 0.01 | R | |||
| LSIL | 27 | 4.04 (±1.06) | 0.02 | 1.00 | R | ||
| ≥HSIL | 44 | 4.54 (±0.88) | <0.001 | 0.20 | 0.39 | R | |
| ≥AGC | 3 | 4.03 (±0.71) | 0.72 | 1.00 | 1.00 | 0.95 | |
| NILM | 43 | 3.34 (±1.18) | R | ||||
| ASC | 14 | 3.84 (±1.27) | 0.82 | R | |||
| 59 | LSIL | 10 | 4.20 (±0.80) | 0.81 | 0.99 | R | |
| ≥HSIL | 15 | 4.13 (±1.03) | 0.34 | 0.98 | 1.00 | R | |
| ≥AGC | 5 | 3.46 (±0.52) | 1.00 | 0.98 | 0.93 | 0.85 | |
| Other types | NILM | 152 | 3.46 (±0.80) | R | |||
| ASC | 45 | 3.44 (±0.71) | 1.00 | R | |||
| LSIL | 31 | 3.77 (±0.55) | 0.86 | 0.93 | R | ||
| ≥HSIL | 12 | 3.21 (±0.64) | 1.00 | 1.00 | 0.93 | R | |
| ≥AGC | 10 | 3.68 (±0.23) | 0.99 | 0.99 | 1.00 | 0.99 |
Notes: Other types, HR-HPV types 35, 39, 51, 66, and 68.
a
A woman was counted multiple times if she was positive for ≥2 HR-HPV types.
b
Estimated by one-way ANOVA with Scheffe’s method for pair-wise multiple comparisons.
Abbreviations: 14 HR-HPVs, add up the log10-transformed viral load of HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68; ≥AGC, atypical gland cells or adenocarcinoma; ASC, atypical squamous cells; HPV, human papillomavirus; ≥HSIL, high-grade squamous intraepithelial lesion or worse; LSIL, low-grade squamous intraepithelial lesion; N/A, not available; NILM, negative for intraepithelial lesion or malignancy; R, reference.